The structure of the dopamine D₃ receptor bound to cariprazine reveals principles for partial agonists with designed pharmacology.

Authors

Eliane Hadas Yardeni, Dóra Judit Kiss, Julie Sanchez, Keshet Shavit, Dénes Szepesi Kovács, Attila Egyed, Caleb D Vogt, Supriya A Gaitonde, Jacqueline Glenn, Meritxell Canals, Michel Bouvier, Amy Hauck Newman, J Robert Lane, György M Keserű, Moran Shalev-Benami

Published in

Science advances. Volume 12. Issue 35. Pages eaef7411. Aug 28, 2026. Epub Aug 28, 2026.

Abstract

The third-generation antipsychotic cariprazine is a low-efficacy partial agonist of the dopamine D₃ receptor (D₃R). Here, we report the cryo-electron microscopy structure of cariprazine bound to D₃R, establishing a framework for understanding ligand recognition in this receptor. We further determine structures of D₃R in complex with a series of cariprazine derivatives spanning inverse agonists to high-efficacy partial agonists. Integration of structural data with pharmacological profiling and molecular dynamics simulations reveals how subtle chemical modifications translate into distinct functional outcomes. Determinants distinguishing agonism from inverse agonism are well defined, whereas differences among partial agonists arise from small positional shifts of the ligand within the orthosteric binding site. In contrast, the extended binding site primarily modulates ligand stability, affinity, and receptor selectivity. These findings establish a mechanistic link between bitopic ligand architecture and receptor activation, providing a "ligand-centric" view of D₃R signaling. Leveraging these principles, we designed and validated cariprazine derivatives with enhanced D₃/D₂ selectivity and partial agonist activity. Together, this work provides a structural and pharmacological blueprint for the rational design of D₃R-targeting ligands with tailored efficacy and therapeutic profiles.

PMID:
42664351
Bibliographic data and abstract were imported from PubMed on 29 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.